Tag Archives

Archive of posts published in the category: Announces
Apr
13

New Mexico Delegation announces transportation grants for Indian tribes

NEW MEXICO (KRQE) – New Mexico tribes will receive $674,279 in grants from the U.S. Department of Transportation to fund tribal public transportation systems for their communities.

U.S. Senators Tom Udall and Martin Heinrich along with U.S. State Representatives Ben Ray Lujan, Deb Haaland and Xochitl Torres Small made the announcement Monday.

The funds are part of the $2 trillion Coronavirus Aid, Relief and Economic Security Act that the New Mexico delegation voted to pass in Congress last week. The grants are part of $2 billion in emergency supplemental funding for federal programs benefiting Indian tribes.

CARES Act also established an $8 billion Tribal Coronavirus Relief Fund to make sure Tribes have “one-stop” access to resources.

“Tribes have made it abundantly clear that the effects of COVID-19 on Indian Country will be devastating if they do not receive necessary public health, economic stabilization, and infrastructure resources. As Tribally-owned and operated businesses are forced to shutter to slow the spread of the novel coronavirus, the federal government must now more than ever stand shoulder to should with Tribal governments to continue to provide essential services. Reliable access to transportation is especially important for Tribal communities during this public health crisis so that families can get the resources and health care they need, especially because transportation infrastructure in many Tribal communities is severely inadequate and in disrepair. This additional funding is a step in the right direction. As the vice-chairman of the Senate Indian Affairs Committee, I will keep working to ensure Tribal communities have the full support of the federal government to stay healthy and financially afloat in this challenging time.”

U.S. Sen. Tom Udall (D-N.M.)

“Tribal governments are facing unique challenges during the coronavirus pandemic. In addition to confronting a public health crisis with already strapped medical resources, they are also losing much of the revenue they rely on from Tribal enterprises disappearing. This federal funding support will help make up some of those losses and ensure tribal communities can continue maintaining their transportation services, which is absolutely critical right now for connecting health care workers to those who need medical attention. I will continue doing everything I can to deliver the lifesaving resources tribes in New Mexico need to get through this emergency and rebuild thriving communities when it is over.”

U.S. Sen. Martin Heinrich (D-N.M.)

“Tribes are among the hardest hit of the COVID-19 pandemic, and it’s critical that we support investments that will support Indian Country’s public health, economy, and infrastructure. This critical grant for Tribal Nations will help keep essential services running during this public health crisis. As Congress negotiates another coronavirus response package, I am continuing to work with Tribal leaders to address the needs of their communities.”

U.S. Rep. Ben Ray Luján (D-N.M.)

“Transportation infrastructure is important to ensuring Native Americans have access to the health care and resources to combat the coronavirus, however, Tribes have been left behind for decades. The delegation and I worked hard to make sure the transportation funding available

Apr
7

Bicycle Therapeutics Announces Pipeline Progress Update

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced progress updates across its wholly-owned and partnered programs in oncology and non-oncology indications.

“We and our partners have recently achieved important progress in the advancement of our pipeline that we believe could catalyze the next stage of growth for Bicycle,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “Cancer Research UK has identified a recommended dose, which is within the therapeutic range predicted by preclinical models, for the Phase IIa study of BT1718, which we expect to commence this year. Our next-generation Bicycle Toxin Conjugates (BTCs), BT5528 and BT8009, are quickly progressing through respective stages of development. In addition, we believe our recently announced early discovery collaboration with Genentech will allow us to make considerable investments in expanding our portfolio of immuno-oncology assets, including our wholly-owned programs nearing late preclinical development. Beyond oncology, we continue to make progress on our partnered programs and to execute on our strategy of leveraging our collaborators’ expertise in specific therapeutic areas to advance the development of Bicycle-based medicines across a broad range of serious diseases.”

Dr. Lee continued: “While we expect that the evolving COVID-19 pandemic may impact the pace of clinical development, at this time, we believe the strong progress we’ve achieved across our pipeline to date will enable us to reach our anticipated 2020 milestones as planned.”

BT1718, a potential first-in-class BTC targeting key tumor antigen MT1-MMP

  • Cancer Research UK Completed Phase I Dose Escalation of BT1718 in Patients with Solid Tumors, Established Recommended Phase II Dose (RP2D) at 20 mg/m2. The key objectives were met in a Phase I dose escalation sponsored by Cancer Research UK and evaluating safety and tolerability of BT1718 in an unselected group of patients with advanced solid tumors. Based on study results, Cancer Research UK established an RP2D for the expansion cohorts at 20 mg/m2 administered once weekly. This recommended dose is within the efficacious dose range predicted by preclinical models, in which an equivalent dose level was associated with complete responses. With once-weekly dosing, BT1718 appeared tolerable, with manageable adverse events.

    Though not a key objective of the Phase I portion of the Phase I/IIa study, preliminary signs of anti-tumor activity were observed during the dose escalation. As reported at the European Society of Medical Oncology (ESMO) 2019 Annual Congress, 13 of 24 evaluable patients (54%) had stable disease at the eight-week timepoint, including a patient who experienced a 45% reduction in a target lesion, with findings generally remaining consistent as the trial progressed. Today, Bicycle announced that, in addition, one patient with small cell lung cancer experienced a partial response, with a 68% reduction in a target lesion.

    The Company anticipates that Cancer Research UK will initiate the Phase IIa portion of the Phase I/IIa study of BT1718 in 2020, although timing may be